Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer

NCT07645391 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-06-12

No results posted yet for this study

Summary

This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.

Conditions

  • Prostate Carcinoma

Interventions

OTHER

Non-Interventional Study

Non-interventional study

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Todd M Morgan, MD · University of Michigan Rogel Cancer Center

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2030-01-31
Completion
2030-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07645391 on ClinicalTrials.gov